Alirocumab in lipoprotein apheresis: A synergy for patients with high-Lp(a) |
| |
| Affiliation: | 1. VA Center for Medication Safety/Pharmacy Benefits Management Services, Hines, Ill;2. Jesse Brown VA Medical Center, Chicago, Ill;3. VA Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pa;4. VA Pharmacy Benefits Management Services, Washington DC;5. VA Greater Los Angeles Healthcare System, Los Angeles, Calif;6. David Geffen School of Medicine at UCLA, Los Angeles, Calif;7. University of Pittsburgh School of Pharmacy, Pittsburgh, Pa |
| |
| Abstract: | Until today lipoprotein apheresis (LA) is considered the most effective treatment for patients with high-Lp(a) and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are often combined with LA to dampen the rebound in lipoprotein concentrations. The aim of the present work is to evaluate the effect of dose-adjustment strategy for alirocumab in a small cohort of high-Lp(a) subjects with ischemic heart disease and in chronic LA treatment. Chronic LA effect on Lp(a) levels is a significant reduction in pre-LA Lp(a) concentrations compared to native Lp(a) value (118 [116–119] mg/dl vs 150 [137–155] mg/dl; p < 0.001). Furthermore, the administration of Arilocumab 75 mg after 7 days from LA shows a significant pre-LA reduction in the Lp(a) concentrations respect to those obtained with administration immediately after the LA treatment. In high-Lp(a) patients treated with chronic LA the deferred addition of alirocumab, resulted in lower LDL-cholesterol and Lp(a) values. |
| |
| Keywords: | Alirocumab Hyper-Lp (a) Lipoprotein apheresis PCSK9 inhibitors |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
